In addition, tumor tissue and serum levels of LRG-1 are increased and associated with worse prognosis in numerous malignancies such as melanoma, colorectal, pancreatic, prostate, lung, hepatocellular, and ovarian cancer [18, 20, 21, 24–33]. Here, LRG1 is linked to neoplasm.